ANTX
NASD AN2 Therapeutics, Inc.$4.30 ↑ +0.00 (+0.00%) Trading Up from the previous close of $4.30, $0.11 below the day’s high of $4.41
- YTD change
- +277.19%
- vs 20-day SMA
- -15.57%
- vs 200-day SMA
- +11.09%
Price ranges
Price & Performance
+1.29 (+42.86%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 81.8% away from all-time highs of $23.58
- ANTX is up 277% since the beginning of the year
- ANTX is up 241% over the past 12 months
- ANTX is down 21% over the past 1 month
- 7% of all ANTX investors are betting against ANTX
ANTX reads not so good: price sits above one of the two key moving averages, the 12-month move is +241.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -24.69%
- vs 8-day SMA
- -16.63%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley in 2017 and is headquartered in Menlo Park, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
